Citigroup’s BridgeBio Pharma BBIO Stock Holding History
Bought
Maintained
Sold
Other funds holding BBIO
Citigroup's BBIO Position: Q3 2026 in Review
Citigroup increased its BridgeBio Pharma (BBIO) stake by 94% in Q3 2026, buying an estimated $63.3M and bringing the position to 1,676,463 shares worth $110M. The position accounts for 0.04% of the portfolio, ranked #466.
Citigroup first reported a position in BBIO in Q3 2019 and has held it in 29 quarters since. 471 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.
- Citigroup held 1,676,463 shares of BridgeBio Pharma worth $110M as of Q3 2026.
- Citigroup bought 812,362 BridgeBio Pharma shares in Q3 2026, an estimated $63.3M.
- BridgeBio Pharma made up 0.04% of Citigroup's portfolio in Q3 2026, its #466 holding.
- Citigroup first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 29 quarters since.
- 471 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.
Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.